Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia The NODE-302 Trial (Extension of NODE-301)

Next Previous
Trial Profile

Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia The NODE-302 Trial (Extension of NODE-301)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etripamil (Primary)
  • Indications Paroxysmal supraventricular tachycardia
  • Focus Adverse reactions; Registrational
  • Acronyms NODE-302
  • Sponsors Milestone Pharmaceuticals

    • Most Recent Events

    • 04 Apr 2023 Status changed from completed to discontinued.
    • 06 Mar 2023 According to a Milestone Pharmaceuticals media release, data from this and RAPID extension studies will be included in the etripamil PSVT New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) which is expected in the third quarter of 2023.
    • 30 Apr 2022 According to an Milestone Pharmaceuticals media release, results from this trial will be featured during a late-breaking clinical trial session at the Heart Rhythm Society's Heart Rhythm 2022 meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top